Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Profit After Tax (2023 - 2025)

Historic Profit After Tax for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$57.5 million.

  • Immunome's Profit After Tax fell 2198.94% to -$57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$222.7 million, marking a year-over-year increase of 2705.27%. This contributed to the annual value of -$293.0 million for FY2024, which is 17429.45% down from last year.
  • Latest data reveals that Immunome reported Profit After Tax of -$57.5 million as of Q3 2025, which was down 2198.94% from -$43.4 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Profit After Tax ranged from a high of -$4.3 million in Q1 2023 and a low of -$129.5 million during Q1 2024
  • For the 3-year period, Immunome's Profit After Tax averaged around -$49.3 million, with its median value being -$43.4 million (2025).
  • As far as peak fluctuations go, Immunome's Profit After Tax crashed by 293259.95% in 2024, and later surged by 6784.36% in 2025.
  • Quarter analysis of 3 years shows Immunome's Profit After Tax stood at -$92.6 million in 2023, then grew by 13.37% to -$80.2 million in 2024, then increased by 28.4% to -$57.5 million in 2025.
  • Its Profit After Tax stands at -$57.5 million for Q3 2025, versus -$43.4 million for Q2 2025 and -$41.6 million for Q1 2025.